Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry ...

For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 ...

Discover a recent study where the authors propose a strategic push to double the diagnostic rate of at-risk MASH by 2030.

Dapagliflozin, a SGLT2 inhibitor used for type 2 diabetes, alleviates steatohepatitis and fibrosis in patients with ...

Individuals with diabetes and hypertension are especially at risk and should undergo screening for NAFLD (Non-Alcoholic Fatty ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

Diabetic weight loss medications are effective for people with schizophrenia without affecting psychotic symptoms, University ...

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...